EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte Studie

Promising clinical outcomes of nano‐curcumin treatment as an adjunct therapy in hospitalized COVID ‐19 patients: A randomized, double‐blinded, placebo‐controlled trial

Majid Sadeghizadeh iD, Elahe Asadollahi, Babak Jahangiri, Mahdi Yadollahzadeh, Maryam Mohajeri, Mandana Afsharpad, Farhood Najafi, Nader Rezaie, Mohana Eskandari, Maria Tavakoli-Ardakani, Faezeh Feizabadi, Mohammad Reza Masjedi

Phytotherapy Research · 2023-08 · 37 (8) · 3631-3644

DOI: 10.1002/ptr.7844 ↗

At a glance

Randomisierte kontrollierte Studie in Phytotherapy Research, published online on 2023-04-29. Written by Majid Sadeghizadeh and 11 co-authors. Institution: Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. Major MEDLINE topics: COVID-19, Curcumin. Cited 19 times so far (Crossref); 80 references. Funded by: National Institute of Genetic Engineering and Biotechnology (NIGEB), National Institute for Genetic Engineering and Biotechnology.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Different immunomodulation strategies have been used to manage COVID‐19 due to the complex immune‐inflammatory processes involved in the pathogenesis of this infection. Curcumin with its powerful anti‐inflammatory and antiviral properties could serve as a possible COVID‐19 therapy. In this study, a randomized, double‐blinded, placebo‐controlled trial was performed to investigate the effectiveness and safety of nano‐curcumin oral soft gels as a complementary therapy in moderate–severe COVID‐19 patients. Hydroxychloroquine (HCQ) plus sofosbuvir was routinely administered to all 42 COVID‐19 patients, who were randomly assigned to receive 140 mg of nano‐curcumin or placebo for 14 days. CT scans of the chest were taken, and blood tests were run for all patients at time points of 0, 7, and 14 days. Our results indicated that C‐reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels significantly decreased from baseline in the nano‐curcumin‐treated group on day 7. Furthermore, blood levels of D‐dimer, CRP, serum ferritin, ESR, and inflammatory cytokines including IL‐6, IL‐8, and IL‐10 decreased more significantly in the nano‐curcumin‐treated group after 14 days. Additionally, the nano‐curcumin group showed significant improvements in chest CT scores, oxygen saturation levels, and hospitalization duration. Based on our data, oral administration of nano‐curcumin may be regarded as a promising adjunct treatment for COVID‐19 patients due to its ability to speed up chest clearance and recovery.

Subjects

MeSH terms (MEDLINE)

COVID-19CurcuminHumansSARS-CoV-2HydroxychloroquineCytokinesTreatment OutcomeDouble-Blind Method

Author keywords

COVID-19SARS-CoV-2curcumincytokine stormhydroxychloroquinenano-curcumin

Substances

CurcuminHydroxychloroquineCytokines

Authors and institutions

  • Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
  • Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
  • Firoozgar Medical & Educational Hospital Department of Internal Medicine School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Alborz Nanomed Tech Company, Tehran, Iran.
  • Cancer Control Research Center, Cancer Control Foundation, Iran University of Medical Sciences, Tehran, Iran.
  • Department of Resin and Additives, Institute for Color Science and Technology, Tehran, Iran.

ORCID profiles: Majid Sadeghizadeh

Funding

  • National Institute of Genetic Engineering and Biotechnology (NIGEB)
  • National Institute for Genetic Engineering and Biotechnology

Cite

APA

Sadeghizadeh, M., Asadollahi, E., Jahangiri, B., Yadollahzadeh, M., Mohajeri, M., Afsharpad, M., Najafi, F., Rezaie, N., Eskandari, M., Tavakoli-Ardakani, M., Feizabadi, F., & Masjedi, M. R. (2023). Promising clinical outcomes of nano‐curcumin treatment as an adjunct therapy in hospitalized COVID ‐19 patients: A randomized, double‐blinded, placebo‐controlled trial. Phytotherapy Research, 37(8), 3631-3644. https://doi.org/10.1002/ptr.7844

Vancouver

Sadeghizadeh M, Asadollahi E, Jahangiri B, Yadollahzadeh M, Mohajeri M, Afsharpad M, et al. Promising clinical outcomes of nano‐curcumin treatment as an adjunct therapy in hospitalized COVID ‐19 patients: A randomized, double‐blinded, placebo‐controlled trial. Phytotherapy Research. 2023;37(8):3631-3644. doi:10.1002/ptr.7844

BibTeX
@article{Sadeghizadeh2023,
  author = {Sadeghizadeh, Majid and Asadollahi, Elahe and Jahangiri, Babak and Yadollahzadeh, Mahdi and Mohajeri, Maryam and Afsharpad, Mandana and Najafi, Farhood and Rezaie, Nader and Eskandari, Mohana and Tavakoli-Ardakani, Maria and Feizabadi, Faezeh and Masjedi, Mohammad Reza},
  title = {Promising clinical outcomes of nano‐curcumin treatment as an adjunct therapy in hospitalized COVID ‐19 patients: A randomized, double‐blinded, placebo‐controlled trial},
  journal = {Phytotherapy Research},
  year = {2023},
  volume = {37},
  number = {8},
  pages = {3631--3644},
  doi = {10.1002/ptr.7844}
}
Start for free →